5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bi-allelic loss-of-function variants in TMEM147 cause moderate to profound intellectual disability with facial dysmorphism and pseudo-Pelger-Huët anomaly

      brief-report
      1 , 39 , , 2 , 39 , 3 , 39 , 4 , 5 , 39 , 2 , 1 , 1 , 6 , 7 , 8 , 9 , 10 , 11 , 11 , 12 , 1 , 1 , 13 , 9 , 10 , 9 , 10 , 1 , 14 , 15 , 16 , 17 , 1 , 1 , 1 , 1 , 13 , 18 , 19 , 18 , 19 , 20 , 20 , 21 , 22 , 23 , 22 , 24 , 24 , 25 , 25 , 25 , 26 , 26 , 26 , 27 , 27 , 27 , 28 , 28 , 28 , 29 , 29 , 30 , 31 , 32 , 32 , 32 , 1 , 33 , 1 , 13 , 1 , 33 , 34 , 35 , 27 , 1 , 13 , 36 , 11 , 12 , 28 , 37 , 38 , 39 , 29 , 39 , 3 , 39 , 2 , 39 , 1 , 13 , 39 , ∗∗
      American Journal of Human Genetics
      Elsevier
      TMEM147, LBR, nuclear envelope instability, Pelger-Huët anomaly, translocon dysfunction, neurodevelopmental disorder, intellectual disability, facial dysmorphism, DNA methylation, transcriptomics

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          The transmembrane protein TMEM147 has a dual function: first at the nuclear envelope, where it anchors lamin B receptor (LBR) to the inner membrane, and second at the endoplasmic reticulum (ER), where it facilitates the translation of nascent polypeptides within the ribosome-bound TMCO1 translocon complex. Through international data sharing, we identified 23 individuals from 15 unrelated families with bi-allelic TMEM147 loss-of-function variants, including splice-site, nonsense, frameshift, and missense variants. These affected children displayed congruent clinical features including coarse facies, developmental delay, intellectual disability, and behavioral problems. In silico structural analyses predicted disruptive consequences of the identified amino acid substitutions on translocon complex assembly and/or function, and in vitro analyses documented accelerated protein degradation via the autophagy-lysosomal-mediated pathway. Furthermore, TMEM147-deficient cells showed CKAP4 (CLIMP-63) and RTN4 (NOGO) upregulation with a concomitant reorientation of the ER, which was also witnessed in primary fibroblast cell culture. LBR mislocalization and nuclear segmentation was observed in primary fibroblast cells. Abnormal nuclear segmentation and chromatin compaction were also observed in approximately 20% of neutrophils, indicating the presence of a pseudo-Pelger-Huët anomaly. Finally, co-expression analysis revealed significant correlation with neurodevelopmental genes in the brain, further supporting a role of TMEM147 in neurodevelopment. Our findings provide clinical, genetic, and functional evidence that bi-allelic loss-of-function variants in TMEM147 cause syndromic intellectual disability due to ER-translocon and nuclear organization dysfunction.

          Graphical abstract

          Abstract

          TMEM147 plays an important role in protein localization and biogenesis. We discovered that individuals with bi-allelic TMEM147 loss-of-function variants show a neurodevelopmental disorder associated with facial dysmorphism and pseudo-Pelger-Huët anomaly. In primary cell lines, we observed nuclear envelope instability accompanied by lamin B receptor mislocalization and ER-translocon dysfunction.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          CADD: predicting the deleteriousness of variants throughout the human genome

          Abstract Combined Annotation-Dependent Depletion (CADD) is a widely used measure of variant deleteriousness that can effectively prioritize causal variants in genetic analyses, particularly highly penetrant contributors to severe Mendelian disorders. CADD is an integrative annotation built from more than 60 genomic features, and can score human single nucleotide variants and short insertion and deletions anywhere in the reference assembly. CADD uses a machine learning model trained on a binary distinction between simulated de novo variants and variants that have arisen and become fixed in human populations since the split between humans and chimpanzees; the former are free of selective pressure and may thus include both neutral and deleterious alleles, while the latter are overwhelmingly neutral (or, at most, weakly deleterious) by virtue of having survived millions of years of purifying selection. Here we review the latest updates to CADD, including the most recent version, 1.4, which supports the human genome build GRCh38. We also present updates to our website that include simplified variant lookup, extended documentation, an Application Program Interface and improved mechanisms for integrating CADD scores into other tools or applications. CADD scores, software and documentation are available at https://cadd.gs.washington.edu.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants.

            The vast majority of coding variants are rare, and assessment of the contribution of rare variants to complex traits is hampered by low statistical power and limited functional data. Improved methods for predicting the pathogenicity of rare coding variants are needed to facilitate the discovery of disease variants from exome sequencing studies. We developed REVEL (rare exome variant ensemble learner), an ensemble method for predicting the pathogenicity of missense variants on the basis of individual tools: MutPred, FATHMM, VEST, PolyPhen, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP, SiPhy, phyloP, and phastCons. REVEL was trained with recently discovered pathogenic and rare neutral missense variants, excluding those previously used to train its constituent tools. When applied to two independent test sets, REVEL had the best overall performance (p < 10(-12)) as compared to any individual tool and seven ensemble methods: MetaSVM, MetaLR, KGGSeq, Condel, CADD, DANN, and Eigen. Importantly, REVEL also had the best performance for distinguishing pathogenic from rare neutral variants with allele frequencies <0.5%. The area under the receiver operating characteristic curve (AUC) for REVEL was 0.046-0.182 higher in an independent test set of 935 recent SwissVar disease variants and 123,935 putatively neutral exome sequencing variants and 0.027-0.143 higher in an independent test set of 1,953 pathogenic and 2,406 benign variants recently reported in ClinVar than the AUCs for other ensemble methods. We provide pre-computed REVEL scores for all possible human missense variants to facilitate the identification of pathogenic variants in the sea of rare variants discovered as sequencing studies expand in scale.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Predicting Splicing from Primary Sequence with Deep Learning

                Bookmark

                Author and article information

                Contributors
                Journal
                Am J Hum Genet
                Am J Hum Genet
                American Journal of Human Genetics
                Elsevier
                0002-9297
                1537-6605
                30 August 2022
                06 October 2022
                30 August 2022
                : 109
                : 10
                : 1909-1922
                Affiliations
                [1 ]UMR1231 GAD, Inserm, Université Bourgogne-Franche Comté, Dijon, France
                [2 ]Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy
                [3 ]University Grenoble Alpes, Inserm, CNRS, Institute for Advanced Biosciences, 38000 Grenoble, France
                [4 ]Clinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt
                [5 ]Armed Forces College of Medicine, Cairo, Egypt
                [6 ]Biology Division, Department of Biological Hematology, Dijon Hospital, 21000 Dijon, France
                [7 ]Université Paris Cité, UMR 1141 NeuroDiderot, Inserm, 75019 Paris, France
                [8 ]Service de Neuropédiatrie, reference center for leukodystrophies, APHP, Hopital Robert Debré, 75019 Paris, France
                [9 ]Service de Génétique Médicale, CHU Nantes, Nantes, France
                [10 ]Université de Nantes, CHU Nantes, CNRS, Inserm, l'Institut du Thorax, 44000 Nantes, France
                [11 ]Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada
                [12 ]Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 3K7, Canada
                [13 ]Unité Fonctionnelle Innovation en Diagnostic Génomique des Maladies Rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France
                [14 ]Division of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
                [15 ]Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
                [16 ]Women Wellness and Research Center Hamad Medical Corporation, Doha, Qatar
                [17 ]Institute of Human Genetics, University Medical Center, Leipzig, Germany
                [18 ]Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
                [19 ]Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK
                [20 ]Medical Genetics, St George’s University Hospitals NHS FT, London SW17 0RE, UK
                [21 ]The Portland Hospital, 205-209 Great Portland St, London W1W 5AH, UK
                [22 ]Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA
                [23 ]Rady Children’s Institute for Genomic Medicine, San Diego, La Jolla, CA 92093, USA
                [24 ]Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea
                [25 ]3billion, Inc, Seoul, South Korea
                [26 ]Children’s Hospital and University of Child Health Lahore, Lahore, Pakistan
                [27 ]CENTOGENE GmbH, 18055 Rostock, Germany
                [28 ]Laboratory of Human Genetics & Therapeutics, Genome Institute of Singapore, A STAR, Singapore, Singapore
                [29 ]Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
                [30 ]Service d’Hématologie cellulaire et hémostase bioclinique, CHU Rennes, Rennes, France
                [31 ]Clinical and Chemical Pathology Department, Medical Research and Clinical Studies Institute National Research Centre, Cairo, Egypt
                [32 ]Service de Médecine Génomique des Maladies Rares, Hôpital Necker-Enfant Malades, AP-HP, Paris, France
                [33 ]Centre de Référence maladies rares « Anomalies du Développement et syndromes malformatifs », Centre de Génétique, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France
                [34 ]Service de Génétique Clinique, Centre Référence Anomalies du Développement CLAD Ouest, Univ Rennes, Rennes, France
                [35 ]Institut de Génétique et Développement de Rennes, CNRS Inserm UMR 6290, ERL 1305, Univ Rennes, Rennes, France
                [36 ]Centre de référence maladies rares « déficiences intellectuelles de causes rares », Centre de Génétique, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France
                [37 ]Medical Genetics Department, School of Medicine, Koç University, Istanbul, Turkey
                [38 ]Smart-Health Initiative, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia
                Author notes
                []Corresponding author quentin.thomas@ 123456chu-dijon.fr
                [∗∗ ]Corresponding author antonio.vitobello@ 123456u-bourgogne.fr
                [39]

                These authors contributed equally

                Article
                S0002-9297(22)00360-3
                10.1016/j.ajhg.2022.08.008
                9606387
                36044892
                b70bde01-f1e4-426f-ad38-169a31507a99
                © 2022 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 11 June 2022
                : 9 August 2022
                Categories
                Report

                Genetics
                tmem147,lbr,nuclear envelope instability,pelger-huët anomaly,translocon dysfunction,neurodevelopmental disorder,intellectual disability,facial dysmorphism,dna methylation,transcriptomics

                Comments

                Comment on this article